By Professor Richard Bryan Lock

Book Chapters

Lock RB; Szymanska B; Carol H; Lock RB, 2011, 'Preclinical Evaluation', in Saha V; Kearns P (ed.), New Agents for the Treatment of Acute Lymphoblastic Leukemia, Springer, New York, Dordrecht, Heidelberg, London, pp. 39 - 60, http://dx.doi.org/10.1007/978-1-4419-8459-3_3

Smith M; Meenakshi D; Wheatley K; Lock RB; Hunsberger S, 2011, 'Strategies for New Agent Development and Clinical Trial Considerations', in Reaman GH; Smith FO (ed.), Childhood Leukemia, Springer-Verlag, Berlin, pp. 215 - 241

Lock RB; Murphy K, 2005, 'Immunodetecting members of the Bcl-2 family of proteins', in Blumenthal RD (ed.), Methods in Molecular Medicine, vol III: Chemosensitivity: Vol 2, Humana Press, Totowa NJ, pp. 83 - 96

Lock RB; Murphy KM, 2005, 'Immunodetecting members of the Bcl-2 family of proteins.', in Blumenthal RD (ed.), Methods in Molecular Medicine, Vol2: In Vivo Models, Imaging, and Molecular Regulators, pp. 83 - 96

Lock RB; Papa R; Liem N, 2005, 'Preclinical Testing of Antileukemic Drugs Using an In Vivo Model of Systemic Disease', in Blumenthal RD (ed.), Methods in Molecular Medicine, vol III: Chemosensitivity: Vol 2, Humana Press, Totowa, NJ, pp. 323 - 334, http://dx.doi.org/10.1385/1-59259-889-7:323

Lock RB; Liem NL; Papa RA, 2005, 'Preclinical testing of antileukemic drugs using an in vivo model of systemic disease', in Blumenthal ED (ed.), Methods in Molecular Medicine: Vol 2: In Vivo Models, Imaging and Molecular Regulators, pp. 323 - 334

Lock RB, 1994, 'Determinants of etoposide cytotoxicity in vitro', in Valeriote FA; Corbett TH; Baker LH (ed.), Anticancer Drug Discovery and Development, Kluwer Academic Publishers, Boston, pp. 347 - 363

Whelan RDH; Hosking LK; Shellard SA; Lock RB; Hill BT, 1990, 'The differential expression of resistance to etoposide, vincristine, Adriamycin and Novantrone in human tumour cell lines in vitro: "typical" and "atypical" multidrug resistance', in Osieka R; Seeber S; Enghofer E (ed.), Chemotherapieresistenz, De Gruyter, pp. 41 - 50, http://dx.doi.org/10.1515/9783110857689-005

Hill BT; Whelan RDH; Hosking LK; Lock RB, 1989, 'Investigations of antitumour drug resistance using human tumour cell lines in vitro', in Ghione M; Ramsa L (ed.), Resistance to Antitumor Agents, Harwood Academic Press, London, pp. 62 - 71

Ross WE; Lock RB; Chow KC; Latham M; Sullivan D, 1989, 'Pathways of resistance to topoisomerase II inhibitors', in Tapiero H; Robert J; Lampidis TJ (ed.), Anticancer Drugs, Colloque INSERM/John Libbey Eurotext Ltd, pp. 93 - 101

Hill BT; Lock RB, 1989, 'Tumor cell resistance to etoposide (VP-16) - A review', in Resistance to Antineoplastic Drugs, CRC Press, Boca Raton, Florida, pp. 185 - 205

Journal articles

Truong P; Shen S; Joshi S; Islam MI; Zhong L; Raftery MJ; Afrasiabi A; Alinejad-Rokny H; Nguyen M; Zou X; Bhuyan GS; Sarowar CH; Ghodousi ES; Stonehouse O; Mohamed S; Toscan CE; Connerty P; Kakadia PM; Bohlander SK; Michie KA; Larsson J; Lock RB; Walkley CR; Thoms JAI; Jolly CJ; Pimanda JE, 2024, 'TOPORS E3 ligase mediates resistance to hypomethylating agent cytotoxicity in acute myeloid leukemia cells', Nature Communications, 15, pp. 7360, http://dx.doi.org/10.1038/s41467-024-51646-6

Toscan CE; McCalmont H; Ashoorzadeh A; Lin X; Fu Z; Doculara L; Kosasih HJ; Cadiz R; Zhou A; Williams S; Evans K; Khalili F; Cai R; Yeats KL; Gifford AJ; Pickford R; Mayoh C; Xie J; Henderson MJ; Trahair TN; Patterson AV; Smaill JB; de Bock CE; Lock RB, 2024, 'The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia.', Blood Cancer J, 14, pp. 192, http://dx.doi.org/10.1038/s41408-024-01180-x

Xu W; Tian F; Tai X; Song G; Liu Y; Fan L; Weng X; Yang E; Wang M; Bornhäuser M; Zhang C; Lock RB; Wong JWH; Wang J; Jing D; Mi JQ, 2024, 'ETV6::ACSL6 translocation-driven super-enhancer activation leads to eosinophilia in acute lymphoblastic leukemia through IL-3 overexpression', Haematologica, 109, pp. 2445 - 2446, http://dx.doi.org/10.3324/haematol.2023.284121

Lau LMS; Khuong-Quang DA; Mayoh C; Wong M; Barahona P; Ajuyah P; Senapati A; Nagabushan S; Sherstyuk A; Altekoester AK; Fuentes-Bolanos NA; Yeung V; Sullivan A; Omer N; Diamond Y; Jessop S; Battaglia L; Zhukova N; Cui L; Lin A; Gifford AJ; Fleuren EDG; Dalla-Pozza L; Moore AS; Khaw SL; Eisenstat DD; Gottardo NG; Wood PJ; Tapp H; Alvaro F; McCowage G; Nicholls W; Hansford JR; Manoharan N; Kotecha RS; Mateos MK; Lock RB; Tyrrell V; Haber M; Trahair TN; Cowley MJ; Ekert PG; Marshall GM; Ziegler DS, 2024, 'Precision-guided treatment in high-risk pediatric cancers', Nature Medicine, 30, pp. 1913 - 1922, http://dx.doi.org/10.1038/s41591-024-03044-0

Karsa M; Xiao L; Ronca E; Bongers A; Spurling D; Karsa A; Cantilena S; Mariana A; Failes TW; Arndt GM; Cheung LC; Kotecha RS; Sutton R; Lock RB; Williams O; de Boer J; Haber M; Norris MD; Henderson MJ; Somers K, 2024, 'FDA-approved disulfiram as a novel treatment for aggressive leukemia', Journal of Molecular Medicine, 102, pp. 507 - 519, http://dx.doi.org/10.1007/s00109-023-02414-4

Randall J; Evans K; Watts B; Kosasih HJ; Smith CM; Earley EJ; Erickson SW; Jocoy EL; Bult CJ; Teicher BA; de Bock CE; Smith MA; Lock RB, 2024, 'In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts', Experimental Hematology, 132, pp. 104176, http://dx.doi.org/10.1016/j.exphem.2024.104176

Mohamed SMA; Schofield P; McCalmont H; Moles E; Friedrich KH; Kavallaris M; Christ D; Bayat N; Lock RB, 2024, 'An antibody fragment-decorated liposomal conjugate targets Philadelphia-like acute lymphoblastic leukemia', International Journal of Biological Macromolecules, 254, pp. 127596, http://dx.doi.org/10.1016/j.ijbiomac.2023.127596

Kim Duong HT; Abdibastami A; Gloag L; Bongers A; Shanehsazzadeh S; Nelson M; Cousins A; Bayat N; McCalmont H; Lock RB; Sulway S; Biazick J; Justin Gooding J; Tilley RD; Gooding J; Duong HTK, 2023, 'Small zinc doped iron oxide tracers for magnetic particle imaging', Journal of Magnetism and Magnetic Materials, 587, http://dx.doi.org/10.1016/j.jmmm.2023.171304

Mayoh C; Mao J; Xie J; Tax G; Chow SO; Cadiz R; Pazaky K; Barahona P; Ajuyah P; Trebilcock P; Malquori A; Gunther K; Avila A; Yun DY; Alfred S; Gopalakrishnan A; Kamili A; Wong M; Cowley MJ; Jessop S; Lau LMS; Trahair TN; Ziegler DS; Fletcher JI; Gifford AJ; Tsoli M; Marshall GM; Haber M; Tyrrell V; Failes TW; Arndt GM; Lock RB; Ekert PG; M Dolman ME; Wong-Erasmus M; Ajuyah P, 2023, 'High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer', Cancer Research, 83, pp. 2716 - 2732, http://dx.doi.org/10.1158/0008-5472.CAN-22-3702

Randall J; Evans K; Watts B; Smith CM; Hughes K; Earley EJ; Erickson SW; Pachter JA; Teicher BA; Smith MA; Lock RB, 2023, 'In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts', Pediatric Blood and Cancer, 70, pp. e30398, http://dx.doi.org/10.1002/pbc.30398

Moles E; Howard CB; Huda P; Karsa M; McCalmont H; Kimpton K; Duly A; Chen Y; Huang Y; Tursky ML; Ma D; Bustamante S; Pickford R; Connerty P; Omari S; Jolly CJ; Joshi S; Shen S; Pimanda JE; Dolnikov A; Cheung LC; Kotecha RS; Norris MD; Haber M; de Bock CE; Somers K; Lock RB; Thurecht KJ; Kavallaris M; Moles Meler E, 2023, 'Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia', Science translational medicine, 15, pp. eabm1262 - eabm1262, http://dx.doi.org/10.1126/scitranslmed.abm1262

Tremblay CS; Saw J; Boyle JA; Haigh K; Litalien V; McCalmont HR; Evans K; Lock RB; Jane SM; Haigh JJ; Curtis DJ, 2023, 'STAT5 activation promotes progression and chemotherapy-resistance in early T-cell precursor acute lymphoblastic leukemia', Blood, 142, http://dx.doi.org/10.1182/blood.2022016322

Germon ZP; Sillar JR; Mannan A; Duchatel RJ; Staudt D; Murray HC; Findlay IJ; Jackson ER; McEwen HP; Douglas AM; McLachlan T; Schjenken JE; Skerrett-Byrne DA; Huang H; Melo-Braga MN; Plank MW; Alvaro F; Chamberlain J; De Iuliis G; Aitken RJ; Nixon B; Wei AH; Enjeti AK; Huang Y; Lock RB; Larsen MR; Lee H; Vaghjiani V; Cain JE; de Bock CE; Verrills NM; Dun MD, 2023, 'Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies', Science Signaling, 16, pp. 1 - 18, http://dx.doi.org/10.1126/scisignal.abp9586

Hughes K; Evans K; Earley EJ; Smith CM; Erickson SW; Stearns T; Philip VM; Neuhauser SB; Chuang JH; Jocoy EL; Bult CJ; Teicher BA; Smith MA; Lock RB, 2023, 'In vivo activity of the dual SYK/FLT3 inhibitor TAK-659 against pediatric acute lymphoblastic leukemia xenografts', Pediatric Blood and Cancer, 70, pp. e30503, http://dx.doi.org/10.1002/pbc.30503

Connerty P; Lock RB, 2023, 'The tip of the iceberg—The roles of long noncoding RNAs in acute myeloid leukemia', Wiley Interdisciplinary Reviews: RNA, 14, pp. e1796, http://dx.doi.org/10.1002/wrna.1796

Shah K; Nasimian A; Ahmed M; Al Ashiri L; Denison L; Sime W; Bendak K; Kolosenko I; Siino V; Levander F; Palm-Apergi C; Massoumi R; Lock RB; Kazi JU, 2023, 'PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia', Blood Cancer Journal, 13, pp. 139 - 139, http://dx.doi.org/10.1038/s41408-023-00914-7

Pearson HCL; Hunt KV; Trahair TN; Lock RB; Lee HJ; De Bock CE, 2022, 'The Promise of Single-cell Technology in Providing New Insights into the Molecular Heterogeneity and Management of Acute Lymphoblastic Leukemia', HemaSphere, 6, pp. E734, http://dx.doi.org/10.1097/HS9.0000000000000734

Xiao L; Karsa M; Ronca E; Bongers A; Kosciolek A; El-Ayoubi A; Revalde JL; Seneviratne JA; Cheung BB; Cheung LC; Kotecha RS; Newbold A; Bjelosevic S; Arndt GM; Lock RB; Johnstone RW; Gudkov AV; Gurova KV; Haber M; Norris MD; Henderson MJ; Somers K, 2022, 'The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression', Frontiers in Oncology, 12, pp. 863329, http://dx.doi.org/10.3389/fonc.2022.863329

Doculara L; Trahair TN; Bayat N; Lock RB, 2022, 'Circulating Tumor DNA in Pediatric Cancer', Frontiers in Molecular Biosciences, 9, pp. 885597, http://dx.doi.org/10.3389/fmolb.2022.885597

Lau LMS; Mayoh C; Xie J; Barahona P; MacKenzie KL; Wong M; Kamili A; Tsoli M; Failes TW; Kumar A; Mould EVA; Gifford A; Chow SO; Pinese M; Fletcher JI; Arndt GM; Khuong-Quang DA; Wadham C; Batey D; Eden G; Trebilcock P; Joshi S; Alfred S; Gopalakrishnan A; Khan A; Grebert Wade D; Strong PA; Manouvrier E; Morgan LT; Span M; Lim JY; Cadiz R; Ung C; Thomas DM; Tucker KM; Warby M; McCowage GB; Dalla-Pozza L; Byrne JA; Saletta F; Fellowes A; Fox SB; Norris MD; Tyrrell V; Trahair TN; Lock RB; Cowley MJ; Ekert PG; Haber M; Ziegler DS; Marshall GM; Trahair T, 2022, 'In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer', EMBO Molecular Medicine, 14, pp. emmm202114608, http://dx.doi.org/10.15252/emmm.202114608

Mesbahi Y; Trahair TN; Lock RB; Connerty P, 2022, 'Exploring the Metabolic Landscape of AML: From Haematopoietic Stem Cells to Myeloblasts and Leukaemic Stem Cells', Frontiers in Oncology, 12, pp. 807266, http://dx.doi.org/10.3389/fonc.2022.807266

Cheung LC; Aya-Bonilla C; Cruickshank MN; Chiu SK; Kuek V; Anderson D; Chua GA; Singh S; Oommen J; Ferrari E; Hughes AM; Ford J; Kunold E; Hesselman MC; Post F; Faulk KE; Breese EH; Guest EM; Brown PA; Loh ML; Lock RB; Kees UR; Jafari R; Malinge S; Kotecha RS, 2022, 'Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy', Leukemia, 37, pp. 1 - 11, http://dx.doi.org/10.1038/s41375-022-01746-3

Tremblay CS; Chiu SK; Saw J; McCalmont H; Litalien V; Boyle J; Sonderegger SE; Chau N; Evans K; Cerruti L; Salmon JM; McCluskey A; Lock RB; Robinson PJ; Jane SM; Curtis DJ, 2021, 'Author Correction: Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells (Nature Communications, (2020), 11, 1, (6211), 10.1038/s41467-020-20091-6)', Nature Communications, 12, pp. 1288, http://dx.doi.org/10.1038/s41467-021-21688-1

Van Thillo Q; De Bie J; Seneviratne JA; Demeyer S; Omari S; Balachandran A; Zhai V; Tam WL; Sweron B; Geerdens E; Gielen O; Provost S; Segers H; Boeckx N; Marshall GM; Cheung BB; Isobe K; Kato I; Takita J; Amos TG; Deveson IW; McCalmont H; Lock RB; Oxley EP; Garwood MM; Dickins RA; Uyttebroeck A; Carter DR; Cools J; de Bock CE, 2021, 'Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia', Nature Communications, 12, pp. 4164, http://dx.doi.org/10.1038/s41467-021-24442-9

Mohamed SMA; Wohlmann A; Schofield P; Sia KCS; McCalmont H; Savvides SN; Verstraete K; Kavallaris M; Christ D; Friedrich KH; Bayat N; Lock RB, 2021, 'A recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemia', International Journal of Biological Macromolecules, 190, pp. 214 - 223, http://dx.doi.org/10.1016/j.ijbiomac.2021.08.194

Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB, 2021, 'Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia', Leukemia, 35, pp. 3101 - 3112, http://dx.doi.org/10.1038/s41375-021-01248-8

Connerty P; Moles E; de Bock CE; Jayatilleke N; Smith JL; Meshinchi S; Mayoh C; Kavallaris M; Lock RB; Moles Meler E, 2021, 'Development of siRNA-loaded lipid nanoparticles targeting long non-coding RNA LINC01257 as a novel and safe therapeutic approach for t(8;21) pediatric acute myeloid leukemia', Pharmaceutics, 13, pp. 1681, http://dx.doi.org/10.3390/pharmaceutics13101681

Li J; Hlavka-Zhang J; Shrimp JH; Piper C; Dupere-Richer D; Roth JS; Jing D; Casellas Roman HL; Troche C; Swaroop A; Kulis M; Oyer JA; Will CM; Shen M; Riva A; Bennett RL; Ferrando AA; Hall MD; Lock RB; Licht JD, 2021, 'PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia.', Cancer Discov, 12, pp. 1 - 46, http://dx.doi.org/10.1158/2159-8290.CD-20-1771

Karsa M; Kosciolek A; Bongers A; Mariana A; Failes T; Gifford AJ; Kees UR; Cheung LC; Kotecha RS; Arndt GM; Haber M; Norris MD; Sutton R; Lock RB; Henderson MJ; Somers K, 2021, 'Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin', British Journal of Cancer, 125, pp. 55 - 64, http://dx.doi.org/10.1038/s41416-021-01332-x

Murray HC; Enjeti AK; Kahl RGS; Flanagan HM; Sillar J; Skerrett-Byrne DA; Al Mazi JG; Au GG; de Bock CE; Evans K; Smith ND; Anderson A; Nixon B; Lock RB; Larsen MR; Verrills NM; Dun MD, 2021, 'Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia', Leukemia, 35, pp. 1782 - 1787, http://dx.doi.org/10.1038/s41375-020-01050-y

Di Grande A; Peirs S; Donovan PD; Van Trimpont M; Morscio J; Lintermans B; Reunes L; Vandamme N; Goossens S; Nguyen HA; Lavie A; Lock RB; Prehn JHM; Van Vlierberghe P; Ní Chonghaile T, 2021, 'The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL.', Blood Advances, 5, pp. 1963 - 1976, http://dx.doi.org/10.1182/bloodadvances.2021004177

Matthijssens F; Sharma ND; Nysus M; Nickl CK; Kang H; Perez DR; Lintermans B; Van Loocke W; Roels J; Peirs S; Demoen L; Pieters T; Reunes L; Lammens T; De Moerloose B; Van Nieuwerburgh F; Deforce DL; Cheung LC; Kotecha RS; Risseeuw MDP; Van Calenbergh S; Takarada T; Yoneda Y; Van Delft FW; Lock RB; Merkley SD; Chigaev A; Sklar LA; Mullighan CG; Loh ML; Winter SS; Hunger SP; Goossens S; Castillo EF; Ornatowski W; Van Vlierberghe P; Matlawska-Wasowska K, 2021, 'RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia', Journal of Clinical Investigation, 131, http://dx.doi.org/10.1172/JCI141566

Xie J; Kumar A; Dolman MEM; Mayoh C; Khuong-Quang DA; Cadiz R; Wong-Erasmus M; Mould EVA; Grebert-Wade D; Barahona P; Kamili A; Tsoli M; Failes TW; Chow SO; Bhatia K; Marshall GM; Ziegler DS; Haber M; Lock RB; Tyrrell V; Lau L; Athanasatos P; Gifford AJ; Arndt G, 2021, 'The important role of routine cytopathology in pediatric precision oncology', Cancer Cytopathology, 129, pp. 805 - 818, http://dx.doi.org/10.1002/cncy.22448

Tremblay CS; Chiu SK; Saw J; McCalmont H; Litalien V; Boyle J; Sonderegger SE; Chau N; Evans K; Cerruti L; Salmon JM; McCluskey A; Lock RB; Robinson PJ; Jane SM; Curtis DJ, 2020, 'Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells', Nature Communications, 11, pp. 6211, http://dx.doi.org/10.1038/s41467-020-20091-6

Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB, 2020, 'Targeting TSLP-induced tyrosine kinase signaling pathways in CRLF2-Rearranged Ph-like ALL', Molecular Cancer Research, 18, pp. 1767 - 1776, http://dx.doi.org/10.1158/1541-7786.MCR-19-1098

Wong M; Mayoh C; Lau LMS; Khuong-Quang DA; Pinese M; Kumar A; Barahona P; Wilkie EE; Sullivan P; Bowen-James R; Syed M; Martincorena I; Abascal F; Sherstyuk A; Bolanos NA; Baber J; Priestley P; Dolman MEM; Fleuren EDG; Gauthier ME; Mould EVA; Gayevskiy V; Gifford AJ; Grebert-Wade D; Strong PA; Manouvrier E; Warby M; Thomas DM; Kirk J; Tucker K; O’Brien T; Alvaro F; McCowage GB; Dalla-Pozza L; Gottardo NG; Tapp H; Wood P; Khaw SL; Hansford JR; Moore AS; Norris MD; Trahair TN; Lock RB; Tyrrell V; Haber M; Marshall GM; Ziegler DS; Ekert PG; Cowley MJ; O'Brien T; Wong-Erasmus M, 2020, 'Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer', Nature Medicine, 26, pp. 1742 - 1753, http://dx.doi.org/10.1038/s41591-020-1072-4

Alruwetei AM; Bendak K; Yadav BD; Carol H; Evans K; Mayoh C; Sutton R; Marshall GM; Lock RB, 2020, 'Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia', British Journal of Cancer, 123, pp. 742 - 751, http://dx.doi.org/10.1038/s41416-020-0933-4

Lim JT; Singh N; Leuvano LA; Calvert VS; Petricoin EF; Teachey DT; Lock RB; Padi M; Kraft AS; Padi SKR, 2020, 'PIM kinase inhibitors block the growth of primary T-cell acute lymphoblastic leukemia: Resistance pathways identified by network modeling analysis', Molecular Cancer Therapeutics, 19, pp. 1809 - 1821, http://dx.doi.org/10.1158/1535-7163.MCT-20-0160

Korotchkina L; Kazyulkin D; Komarov PG; Polinsky A; Andrianova EL; Joshi S; Gupta M; Vujcic S; Kononov E; Toshkov I; Tian Y; Krasnov P; Chernov MV; Veith J; Antoch MP; Middlemiss S; Somers K; Lock RB; Norris MD; Henderson MJ; Haber M; Chernova OB; Gudkov AV, 2020, 'OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis', Leukemia, 34, pp. 1828 - 1839, http://dx.doi.org/10.1038/s41375-019-0692-5

Back to profile page